Granite Selected for Tahoe Cedars Water Reconstruction Project
WATSONVILLE, Calif., June 12, 2025--(BUSINESS WIRE)--Granite (NYSE:GVA) has been selected by the Tahoe City Public Utility District (TCPUD) for the approximately $3 million preconstruction portion of the Tahoe Cedars Water Reconstruction Project under a Progressive Design-Build (PDB) contract. DOWL, LLC has been named the Designer-of-Record. Located in Tahoma, California, along the west shore of Lake Tahoe, this project represents Granite's first PDB contract in the state, marking a significant milestone for the company.
"Our team is honored to be awarded the Tahoe Cedars PDB project and excited to deliver the first PDB project for Granite in California. We look forward to working with TCPUD and DOWL to deliver a project that significantly enhances the water infrastructure for the Tahoe Cedars community while demonstrating the effectiveness of the collaborative PDB process," said Chris Burke, Granite Vice President of Regional Operations.
The Tahoe Cedars project is a critical endeavor aimed at upgrading the aging water infrastructure that was originally constructed in the 1940s. Located in the Tahoe Cedars area, key components of the project include:
Replacing 15 miles of undersized and failing water mains
Relocating 632 water service lines from backyards to the street
Installing 97 new fire hydrants for enhanced fire protection
Adding over 1,000 residential water meters
Preconstruction activities commenced this Spring and are expected to run through early 2026, and the anticipated construction value of the contract is $60 million.
The construction portion of the project is expected to begin in May 2026 and continue through 2029.
About Granite
Granite is America's Infrastructure Company™. Incorporated since 1922, Granite (NYSE:GVA) is one of the largest diversified construction and construction materials companies in the United States as well as a full-suite civil construction provider. Granite's Code of Conduct and strong Core Values guide the Company and its employees to uphold the highest ethical standards. Granite is an industry leader in safety and an award-winning firm in quality and sustainability. For more information, visit the Granite website, graniteconstruction.com, and connect with Granite on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612782008/en/
Contacts
Granite Contacts
Media Erin Kuhlman 831-768-4111Investors Wenjun Xu - 831-761-7861
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Snowflake Gains Momentum in AI and Data Cloud, Says Truist Securities
Snowflake Inc. (NYSE:SNOW) ranks among the best fundamental stocks to buy according to hedge funds. On June 18, Truist Securities restated its Buy rating and $235 price target for Snowflake Inc. (NYSE:SNOW) following encouraging results from the firm's mid-year IT spending survey. The survey revealed that Snowflake's data cloud offerings remained prevalent and suggested that growing momentum would continue. Notably, Truist appeared somewhat surprised by the positive survey results around new product adoption. Truist also noted advancements during Snowflake's recent investor session and user conference, highlighting the company's notable advancements in artificial intelligence over the previous two years. As investments in the AI vertical continue to rise, the research firm believes Snowflake Inc. (NYSE:SNOW) is in an ideal spot to take on additional workloads. Snowflake Inc. (NYSE:SNOW) is an American cloud-based data storage company that operates a platform built on Amazon Web Services, Microsoft Azure, and Google Cloud. It also provides Snowflake Cortex with a set of AI capabilities that employ large language models to analyze unstructured data. While we acknowledge the potential of SNOW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
By GlobeNewswire Published on June 29, 2025, 16:00 IST Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' – making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe – including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio – designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor – please visit here. – ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew [email protected] *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 hours ago
- Yahoo
What Does Yelp Inc.'s (NYSE:YELP) Share Price Indicate?
Yelp Inc. (NYSE:YELP), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$40.93 at one point, and dropping to the lows of US$32.56. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Yelp's current trading price of US$34.38 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Yelp's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The share price seems sensible at the moment according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 15.34x is currently trading slightly below its industry peers' ratio of 16.42x, which means if you buy Yelp today, you'd be paying a decent price for it. And if you believe that Yelp should be trading at this level in the long run, then there's not much of an upside to gain over and above other industry peers. So, is there another chance to buy low in the future? Given that Yelp's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for Yelp Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Yelp's earnings over the next few years are expected to increase by 27%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? YELP's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at YELP? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio? Are you a potential investor? If you've been keeping tabs on YELP, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for YELP, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. At Simply Wall St, we have the analysts estimates which you can view by clicking here. If you are no longer interested in Yelp, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
